drugset / Trial / NCT01483586

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

NCT01483586

Phase 2 Terminated 90 enrolled KangLaiTe USA
RandomizedParallel-groupOpen-labelTreatment

Summary

This research is being done to evaluate the safety and efficacy of the investigational Kanglaite gelcap (KLTc) on PSA in men with prostate cancer when given for twelve months.

Timeline

Start
2011-11
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Kanglaite Traditional medicine (herbal / TCM) 1.35 g Oral
Subject Kanglaite Traditional medicine (herbal / TCM) 2.7 g Oral

Indications